25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

SAREPTA THERAP (AB3A.SG)
Buy, Hold or Sell?

Let's analyze SAREPTA THERAP (AB3A.SG) together

I guess you are interested in SAREPTA THERAP (AB3A.SG). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of SAREPTA THERAP (AB3A.SG). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about SAREPTA THERAP (AB3A.SG)

I send you an email if I find something interesting about SAREPTA THERAP (AB3A.SG).

1. Quick Overview

1.1. Quick analysis of SAREPTA THERAP (AB3A.SG) (30 sec.)










1.2. What can you expect buying and holding a share of SAREPTA THERAP (AB3A.SG)? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€14.52
Expected worth in 1 year
€20.60
How sure are you?
52.4%

+ What do you gain per year?

Total Gains per Share
€6.08
Return On Investment
6.8%

For what price can you sell your share?

Current Price per Share
€89.08
Expected price per share
€81.74 - €122.40
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of SAREPTA THERAP (AB3A.SG) (5 min.)




Live pricePrice per Share (EOD)
€89.08
Intrinsic Value Per Share
€6.85 - €10.15
Total Value Per Share
€21.37 - €24.68

2.2. Growth of SAREPTA THERAP (AB3A.SG) (5 min.)




Is SAREPTA THERAP (AB3A.SG) growing?

Current yearPrevious yearGrowGrow %
How rich?$1.5b$769.4m$427.2m35.7%

How much money is SAREPTA THERAP (AB3A.SG) making?

Current yearPrevious yearGrowGrow %
Making money$58.8m-$133.9m$192.7m327.8%
Net Profit Margin10.5%-53.5%--

How much money comes from the company's main activities?

2.3. Financial Health of SAREPTA THERAP (AB3A.SG) (5 min.)




2.4. Comparing to competitors in the Other industry (5 min.)




  Industry Rankings (Other)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of SAREPTA THERAP (AB3A.SG)?

Welcome investor! SAREPTA THERAP (AB3A.SG)'s management wants to use your money to grow the business. In return you get a share of SAREPTA THERAP (AB3A.SG).

First you should know what it really means to hold a share of SAREPTA THERAP (AB3A.SG). And how you can make/lose money.

Speculation

The Price per Share of SAREPTA THERAP (AB3A.SG) is €89.08. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of SAREPTA THERAP (AB3A.SG).
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in SAREPTA THERAP (AB3A.SG), you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €14.52. Based on the TTM, the Book Value Change Per Share is €1.52 per quarter. Based on the YOY, the Book Value Change Per Share is €1.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of SAREPTA THERAP (AB3A.SG).

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps1.641.8%0.610.7%-1.44-1.6%-1.17-1.3%-1.11-1.2%
Usd Book Value Change Per Share2.983.3%1.651.9%1.201.3%0.240.3%0.750.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.983.3%1.651.9%1.201.3%0.240.3%0.750.8%
Usd Price Per Share125.48-134.09-117.75-112.67-99.15-
Price to Earnings Ratio19.11-194.68--34.52-17.53-14.19-
Price-to-Total Gains Ratio42.12-98.58-270.40-13.94-13.83-
Price to Book Ratio7.96-11.08-14.47-13.19-11.48-
Price-to-Total Gains Ratio42.12-98.58-270.40-13.94-13.83-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share96.69634
Number of shares10
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.650.24
Usd Total Gains Per Share1.650.24
Gains per Quarter (10 shares)16.492.44
Gains per Year (10 shares)65.989.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1066560100
2013212202010
3019818802920
4026425403930
5033032004940
6039638605950
7046245206860
8052851807870
9059458408880
10066065009890

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%5.07.00.041.7%5.015.00.025.0%5.016.00.023.8%5.016.00.023.8%
Book Value Change Per Share4.00.00.0100.0%8.04.00.066.7%10.010.00.050.0%11.010.00.052.4%11.010.00.052.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share4.00.00.0100.0%8.04.00.066.7%10.010.00.050.0%11.010.00.052.4%11.010.00.052.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of SAREPTA THERAP (AB3A.SG) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.7441.520+81%1.103+149%0.225+1120%0.692+297%
Book Value Per Share--14.52411.522+26%7.586+91%8.685+67%7.655+90%
Current Ratio--4.2013.997+5%4.744-11%5.203-19%5.704-26%
Debt To Asset Ratio--0.6150.666-8%0.755-19%0.737-17%0.683-10%
Debt To Equity Ratio--1.5942.019-21%3.094-48%3.194-50%2.786-43%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--8958178300.4009628217205.475-7%7947887507.128+13%7020993185.242+28%7059329142.668+27%
Eps--1.5120.563+169%-1.325+188%-1.082+172%-1.022+168%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--3.6925.883-37%7.316-50%8.272-55%8.888-58%
Free Cash Flow Per Share--0.513-0.860+268%-1.451+383%-0.907+277%-0.970+289%
Free Cash Flow To Equity Per Share--0.979-0.560+157%-1.143+217%0.034+2762%0.076+1183%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--10.154--------
Intrinsic Value_10Y_min--6.847--------
Intrinsic Value_1Y_max---3.560--------
Intrinsic Value_1Y_min---3.500--------
Intrinsic Value_3Y_max---7.208--------
Intrinsic Value_3Y_min---6.952--------
Intrinsic Value_5Y_max---6.650--------
Intrinsic Value_5Y_min---6.473--------
Market Cap--11201697337.60011798719857.975-5%10131616288.628+11%9117455078.642+23%7962525817.751+41%
Net Profit Margin--0.2420.105+131%-0.535+321%-0.558+331%-0.775+421%
Operating Margin----0%-0%-0.1630%-0.4180%
Operating Ratio--0.9551.067-10%1.387-31%1.630-41%1.775-46%
Pb Ratio6.133-30%7.95911.085-28%14.474-45%13.190-40%11.475-31%
Pe Ratio14.729-30%19.113194.679-90%-34.518+281%17.526+9%14.185+35%
Price Per Share89.080-30%115.600123.525-6%108.478+7%103.792+11%91.343+27%
Price To Free Cash Flow Ratio43.410-30%56.333-62.129+210%-20.640+137%-28.572+151%-24.354+143%
Price To Total Gains Ratio32.460-30%42.12398.584-57%270.396-84%13.938+202%13.827+205%
Quick Ratio--1.1671.878-38%2.667-56%1.716-32%1.856-37%
Return On Assets--0.0400.016+157%-0.044+209%-0.034+185%-0.045+212%
Return On Equity--0.1040.044+138%-0.189+282%-0.162+256%-0.165+259%
Total Gains Per Share--2.7441.520+81%1.103+149%0.225+1120%0.692+297%
Usd Book Value--1527684862.4491196723740.858+28%769434722.065+99%826151650.773+85%865999818.729+76%
Usd Book Value Change Per Share--2.9791.649+81%1.198+149%0.244+1120%0.751+297%
Usd Book Value Per Share--15.76612.507+26%8.235+91%9.428+67%8.310+90%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--9724102545.08410451429776.543-7%8627431888.987+13%7621288102.580+28%7662901784.366+27%
Usd Eps--1.6410.611+169%-1.439+188%-1.174+172%-1.109+168%
Usd Free Cash Flow--53961981.746-88182451.853+263%-147078999.040+373%-87679170.676+262%-94697499.848+275%
Usd Free Cash Flow Per Share--0.557-0.933+268%-1.576+383%-0.984+277%-1.053+289%
Usd Free Cash Flow To Equity Per Share--1.062-0.608+157%-1.240+217%0.037+2762%0.083+1183%
Usd Market Cap--12159442459.96512807510405.832-5%10997869481.305+11%9896997487.865+23%8643321775.169+41%
Usd Price Per Share96.696-30%125.484134.086-6%117.752+7%112.666+11%99.153+27%
Usd Profit--159043051.56758807550.515+170%-133989238.615+184%-98853002.759+162%-112171179.641+171%
Usd Revenue--658387375.391475476966.496+38%310822374.808+112%266005751.013+148%237538907.379+177%
Usd Total Gains Per Share--2.9791.649+81%1.198+149%0.244+1120%0.751+297%
 EOD+4 -2MRQTTM+26 -9YOY+28 -75Y+29 -610Y+29 -6

3.3 Fundamental Score

Let's check the fundamental score of SAREPTA THERAP (AB3A.SG) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1514.729
Price to Book Ratio (EOD)Between0-16.133
Net Profit Margin (MRQ)Greater than00.242
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.167
Current Ratio (MRQ)Greater than14.201
Debt to Asset Ratio (MRQ)Less than10.615
Debt to Equity Ratio (MRQ)Less than11.594
Return on Equity (MRQ)Greater than0.150.104
Return on Assets (MRQ)Greater than0.050.040
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of SAREPTA THERAP (AB3A.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose90.700
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About SAREPTA THERAP (AB3A.SG)

  • Other
  • 0

There is no Profile data available for AB3A.SG.

Fundamental data was last updated by Penke on 2025-03-11 18:50:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit SAREPTA THERAP (AB3A.SG) earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare SAREPTA THERAP (AB3A.SG) to the Other industry mean.
  • A Net Profit Margin of 24.2% means that €0.24 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of SAREPTA THERAP (AB3A.SG):

  • The MRQ is 24.2%. The company is making a huge profit. +2
  • The TTM is 10.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ24.2%TTM10.5%+13.7%
TTM10.5%YOY-53.5%+63.9%
TTM10.5%5Y-55.8%+66.3%
5Y-55.8%10Y-77.5%+21.7%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ24.2%5.6%+18.6%
TTM10.5%5.9%+4.6%
YOY-53.5%6.1%-59.6%
5Y-55.8%6.2%-62.0%
10Y-77.5%6.1%-83.6%
4.3.1.2. Return on Assets

Shows how efficient SAREPTA THERAP (AB3A.SG) is using its assets to generate profit.

  • Above 5% is considered healthy but always compare SAREPTA THERAP (AB3A.SG) to the Other industry mean.
  • 4.0% Return on Assets means that SAREPTA THERAP (AB3A.SG) generated €0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of SAREPTA THERAP (AB3A.SG):

  • The MRQ is 4.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.0%TTM1.6%+2.4%
TTM1.6%YOY-4.4%+6.0%
TTM1.6%5Y-3.4%+5.0%
5Y-3.4%10Y-4.5%+1.1%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0%1.3%+2.7%
TTM1.6%1.1%+0.5%
YOY-4.4%1.3%-5.7%
5Y-3.4%1.3%-4.7%
10Y-4.5%1.3%-5.8%
4.3.1.3. Return on Equity

Shows how efficient SAREPTA THERAP (AB3A.SG) is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare SAREPTA THERAP (AB3A.SG) to the Other industry mean.
  • 10.4% Return on Equity means SAREPTA THERAP (AB3A.SG) generated €0.10 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of SAREPTA THERAP (AB3A.SG):

  • The MRQ is 10.4%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 4.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ10.4%TTM4.4%+6.0%
TTM4.4%YOY-18.9%+23.3%
TTM4.4%5Y-16.2%+20.6%
5Y-16.2%10Y-16.5%+0.3%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ10.4%3.7%+6.7%
TTM4.4%3.4%+1.0%
YOY-18.9%3.9%-22.8%
5Y-16.2%3.9%-20.1%
10Y-16.5%3.8%-20.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of SAREPTA THERAP (AB3A.SG).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient SAREPTA THERAP (AB3A.SG) is operating .

  • Measures how much profit SAREPTA THERAP (AB3A.SG) makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare SAREPTA THERAP (AB3A.SG) to the Other industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of SAREPTA THERAP (AB3A.SG):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-16.3%+16.3%
5Y-16.3%10Y-41.8%+25.5%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.7%-12.7%
TTM-8.2%-8.2%
YOY-7.8%-7.8%
5Y-16.3%4.4%-20.7%
10Y-41.8%6.8%-48.6%
4.3.2.2. Operating Ratio

Measures how efficient SAREPTA THERAP (AB3A.SG) is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Other industry mean).
  • An Operation Ratio of 0.96 means that the operating costs are €0.96 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of SAREPTA THERAP (AB3A.SG):

  • The MRQ is 0.955. The company is less efficient in keeping operating costs low.
  • The TTM is 1.067. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.955TTM1.067-0.111
TTM1.067YOY1.387-0.320
TTM1.0675Y1.630-0.564
5Y1.63010Y1.775-0.145
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9551.313-0.358
TTM1.0671.355-0.288
YOY1.3871.375+0.012
5Y1.6301.324+0.306
10Y1.7751.381+0.394
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of SAREPTA THERAP (AB3A.SG).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if SAREPTA THERAP (AB3A.SG) is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Other industry mean).
  • A Current Ratio of 4.20 means the company has €4.20 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of SAREPTA THERAP (AB3A.SG):

  • The MRQ is 4.201. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.997. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.201TTM3.997+0.204
TTM3.997YOY4.744-0.748
TTM3.9975Y5.203-1.206
5Y5.20310Y5.704-0.501
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2011.426+2.775
TTM3.9971.416+2.581
YOY4.7441.538+3.206
5Y5.2031.562+3.641
10Y5.7041.496+4.208
4.4.3.2. Quick Ratio

Measures if SAREPTA THERAP (AB3A.SG) is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare SAREPTA THERAP (AB3A.SG) to the Other industry mean.
  • A Quick Ratio of 1.17 means the company can pay off €1.17 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of SAREPTA THERAP (AB3A.SG):

  • The MRQ is 1.167. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.878. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.167TTM1.878-0.711
TTM1.878YOY2.667-0.790
TTM1.8785Y1.716+0.161
5Y1.71610Y1.856-0.140
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1670.531+0.636
TTM1.8780.553+1.325
YOY2.6670.603+2.064
5Y1.7160.606+1.110
10Y1.8560.609+1.247
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of SAREPTA THERAP (AB3A.SG).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of SAREPTA THERAP (AB3A.SG) assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare SAREPTA THERAP (AB3A.SG) to Other industry mean.
  • A Debt to Asset Ratio of 0.61 means that SAREPTA THERAP (AB3A.SG) assets are financed with 61.5% credit (debt) and the remaining percentage (100% - 61.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of SAREPTA THERAP (AB3A.SG):

  • The MRQ is 0.615. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.666. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.615TTM0.666-0.051
TTM0.666YOY0.755-0.090
TTM0.6665Y0.737-0.071
5Y0.73710Y0.683+0.054
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6150.520+0.095
TTM0.6660.529+0.137
YOY0.7550.523+0.232
5Y0.7370.555+0.182
10Y0.6830.564+0.119
4.5.4.2. Debt to Equity Ratio

Measures if SAREPTA THERAP (AB3A.SG) is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare SAREPTA THERAP (AB3A.SG) to the Other industry mean.
  • A Debt to Equity ratio of 159.4% means that company has €1.59 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of SAREPTA THERAP (AB3A.SG):

  • The MRQ is 1.594. The company is just able to pay all its debts with equity.
  • The TTM is 2.019. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.594TTM2.019-0.425
TTM2.019YOY3.094-1.075
TTM2.0195Y3.194-1.175
5Y3.19410Y2.786+0.408
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5941.095+0.499
TTM2.0191.128+0.891
YOY3.0941.155+1.939
5Y3.1941.338+1.856
10Y2.7861.429+1.357
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings SAREPTA THERAP (AB3A.SG) generates.

  • Above 15 is considered overpriced but always compare SAREPTA THERAP (AB3A.SG) to the Other industry mean.
  • A PE ratio of 19.11 means the investor is paying €19.11 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of SAREPTA THERAP (AB3A.SG):

  • The EOD is 14.729. Based on the earnings, the company is underpriced. +1
  • The MRQ is 19.113. Based on the earnings, the company is fair priced.
  • The TTM is 194.679. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD14.729MRQ19.113-4.385
MRQ19.113TTM194.679-175.566
TTM194.679YOY-34.518+229.198
TTM194.6795Y17.526+177.153
5Y17.52610Y14.185+3.341
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD14.72914.089+0.640
MRQ19.11313.537+5.576
TTM194.67912.493+182.186
YOY-34.51811.191-45.709
5Y17.52612.976+4.550
10Y14.18513.175+1.010
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of SAREPTA THERAP (AB3A.SG):

  • The EOD is 43.410. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 56.333. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is -62.129. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD43.410MRQ56.333-12.924
MRQ56.333TTM-62.129+118.463
TTM-62.129YOY-20.640-41.489
TTM-62.1295Y-28.572-33.557
5Y-28.57210Y-24.354-4.219
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD43.4108.643+34.767
MRQ56.3338.169+48.164
TTM-62.1297.139-69.268
YOY-20.6405.896-26.536
5Y-28.5723.220-31.792
10Y-24.3543.714-28.068
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of SAREPTA THERAP (AB3A.SG) is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Other industry mean).
  • A PB ratio of 7.96 means the investor is paying €7.96 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of SAREPTA THERAP (AB3A.SG):

  • The EOD is 6.133. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.959. Based on the equity, the company is overpriced. -1
  • The TTM is 11.085. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD6.133MRQ7.959-1.826
MRQ7.959TTM11.085-3.126
TTM11.085YOY14.474-3.389
TTM11.0855Y13.190-2.105
5Y13.19010Y11.475+1.714
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD6.1331.532+4.601
MRQ7.9591.404+6.555
TTM11.0851.428+9.657
YOY14.4741.405+13.069
5Y13.1901.718+11.472
10Y11.4751.715+9.760
4.6.2. Total Gains per Share

2.4. Latest News of SAREPTA THERAP (AB3A.SG)

Does SAREPTA THERAP (AB3A.SG) still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from SAREPTA THERAP (AB3A.SG) to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-02-26
22:36
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On RevenueRead
2025-02-26
22:23
Sarepta Therapeutics: Q4 Earnings SnapshotRead
2025-02-26
22:05
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate DevelopmentsRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets3,963,173
Total Liabilities2,435,431
Total Stockholder Equity1,527,742
 As reported
Total Liabilities 2,435,431
Total Stockholder Equity+ 1,527,742
Total Assets = 3,963,173

Assets

Total Assets3,963,173
Total Current Assets3,073,463
Long-term Assets889,710
Total Current Assets
Cash And Cash Equivalents 1,103,010
Short-term Investments 251,782
Net Receivables 601,988
Inventory 749,960
Other Current Assets 9,214
Total Current Assets  (as reported)3,073,463
Total Current Assets  (calculated)2,715,954
+/- 357,509
Long-term Assets
Property Plant Equipment 488,646
Long Term Investments 136,873
Intangible Assets 26,887
Long-term Assets Other 206,959
Long-term Assets  (as reported)889,710
Long-term Assets  (calculated)859,365
+/- 30,345

Liabilities & Shareholders' Equity

Total Current Liabilities731,684
Long-term Liabilities1,703,747
Total Stockholder Equity1,527,742
Total Current Liabilities
Accounts payable 214,442
Total Current Liabilities  (as reported)731,684
Total Current Liabilities  (calculated)214,442
+/- 517,242
Long-term Liabilities
Long term Debt 1,137,124
Capital Lease Obligations Min Short Term Debt205,946
Long-term Liabilities Other 49,150
Long-term Liabilities  (as reported)1,703,747
Long-term Liabilities  (calculated)1,392,220
+/- 311,527
Total Stockholder Equity
Total Stockholder Equity (as reported)1,527,742
Total Stockholder Equity (calculated)0
+/- 1,527,742
Other
Capital Stock10
Common Stock Shares Outstanding 96,900
Net Debt 34,114
Net Invested Capital 2,664,866
Net Working Capital 2,341,779
Property Plant and Equipment Gross 722,791



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
1,963,895
1,747,753
1,702,470
1,822,822
2,947,388
2,883,043
2,780,664
2,984,718
2,765,233
2,759,073
2,662,218
3,147,974
3,056,154
2,996,853
3,156,149
3,128,366
3,059,786
3,125,890
3,109,707
3,264,576
3,224,385
3,424,257
3,599,934
3,963,173
3,963,1733,599,9343,424,2573,224,3853,264,5763,109,7073,125,8903,059,7863,128,3663,156,1492,996,8533,056,1543,147,9742,662,2182,759,0732,765,2332,984,7182,780,6642,883,0432,947,3881,822,8221,702,4701,747,7531,963,895
   > Total Current Assets 
1,671,423
1,427,418
1,362,299
1,468,913
2,547,348
2,459,421
2,322,673
2,485,196
2,271,350
2,265,217
2,185,310
2,604,099
2,530,947
2,469,300
2,625,929
2,557,861
2,488,377
2,472,614
2,450,849
2,579,331
2,464,865
2,683,636
2,685,369
3,073,463
3,073,4632,685,3692,683,6362,464,8652,579,3312,450,8492,472,6142,488,3772,557,8612,625,9292,469,3002,530,9472,604,0992,185,3102,265,2172,271,3502,485,1962,322,6732,459,4212,547,3481,468,9131,362,2991,427,4181,671,423
       Cash And Cash Equivalents 
732,190
808,591
724,829
835,080
1,764,212
1,639,959
1,474,637
1,502,648
1,481,836
1,697,275
1,599,113
2,115,869
1,233,877
868,565
1,038,624
966,777
871,668
851,929
541,932
428,430
427,290
383,622
197,855
1,103,010
1,103,010197,855383,622427,290428,430541,932851,929871,668966,7771,038,624868,5651,233,8772,115,8691,599,1131,697,2751,481,8361,502,6481,474,6371,639,9591,764,212835,080724,829808,591732,190
       Short-term Investments 
612,018
294,478
324,063
289,668
406,940
421,349
341,467
435,923
255,997
30,000
0
0
779,548
1,059,454
1,033,860
1,022,597
1,010,429
1,008,786
1,191,610
1,247,820
963,453
1,076,852
1,000,534
251,782
251,7821,000,5341,076,852963,4531,247,8201,191,6101,008,7861,010,4291,022,5971,033,8601,059,454779,5480030,000255,997435,923341,467421,349406,940289,668324,063294,478612,018
       Net Receivables 
49,718
56,189
67,260
90,409
89,960
94,692
104,488
100,870
117,733
127,050
149,317
152,990
178,194
203,854
201,509
214,628
223,836
236,808
318,855
400,327
378,806
359,997
434,524
601,988
601,988434,524359,997378,806400,327318,855236,808223,836214,628201,509203,854178,194152,990149,317127,050117,733100,870104,48894,69289,96090,40967,26056,18949,718
       Inventory 
140,467
156,569
166,360
171,379
173,168
179,650
220,118
231,961
240,333
268,756
288,469
186,212
198,997
208,095
221,192
203,968
202,675
226,876
244,011
322,859
373,530
485,795
565,924
749,960
749,960565,924485,795373,530322,859244,011226,876202,675203,968221,192208,095198,997186,212288,469268,756240,333231,961220,118179,650173,168171,379166,360156,569140,467
       Other Current Assets 
4,949
5,927
5,109
5,249
5,867
3,222
3,231
4,065
5,369
4,905
5,678
6,142
7,008
9,805
11,059
6,821
9,878
11,459
13,669
12,478
8,076
8,242
7,852
9,214
9,2147,8528,2428,07612,47813,66911,4599,8786,82111,0599,8057,0086,1425,6784,9055,3694,0653,2313,2225,8675,2495,1095,9274,949
   > Long-term Assets 
292,472
320,335
340,171
353,909
400,040
423,622
457,991
499,522
493,883
493,856
476,908
543,875
525,207
527,553
530,220
570,505
571,409
653,276
658,858
685,245
759,520
740,621
914,565
889,710
889,710914,565740,621759,520685,245658,858653,276571,409570,505530,220527,553525,207543,875476,908493,856493,883499,522457,991423,622400,040353,909340,171320,335292,472
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
224,039
244,991
244,878
323,602
345,821
357,106
375,571
400,201
446,686
488,646
488,646446,686400,201375,571357,106345,821323,602244,878244,991224,03900000000000000
       Long Term Investments 
32,359
32,154
31,834
31,937
33,697
33,344
32,769
38,799
40,640
39,971
35,288
34,892
33,394
33,234
33,244
31,321
31,000
31,000
7,500
6,527
41,376
7,606
186,493
136,873
136,873186,4937,60641,3766,5277,50031,00031,00031,32133,24433,23433,39434,89235,28839,97140,64038,79932,76933,34433,69731,93731,83432,15432,359
       Intangible Assets 
11,781
11,825
11,975
12,497
12,813
13,105
13,344
13,628
0
0
0
14,239
0
0
0
7,578
0
0
0
29,620
0
0
0
26,887
26,88700029,6200007,57800014,23900013,62813,34413,10512,81312,49711,97511,82511,781
       Long-term Assets Other 
8,926
11,797
11,660
11,799
11,981
11,603
12,198
12,984
12,407
12,731
12,786
143,285
134,812
145,044
159,685
183,653
191,737
194,981
199,027
212,322
226,464
223,414
221,782
206,959
206,959221,782223,414226,464212,322199,027194,981191,737183,653159,685145,044134,812143,28512,78612,73112,40712,98412,19811,60311,98111,79911,66011,7978,926
> Total Liabilities 
615,331
648,586
707,266
1,004,635
1,802,560
1,840,177
1,888,617
2,222,959
2,229,788
2,273,965
2,192,690
2,219,965
2,199,268
2,270,396
2,725,309
2,743,416
2,347,037
2,384,479
2,345,350
2,405,239
2,263,193
2,347,188
2,378,863
2,435,431
2,435,4312,378,8632,347,1882,263,1932,405,2392,345,3502,384,4792,347,0372,743,4162,725,3092,270,3962,199,2682,219,9652,192,6902,273,9652,229,7882,222,9591,888,6171,840,1771,802,5601,004,635707,266648,586615,331
   > Total Current Liabilities 
137,366
162,089
215,856
264,767
306,429
354,896
378,388
416,026
364,736
425,022
373,443
452,733
454,962
545,566
602,916
619,604
536,884
498,654
450,743
653,659
608,709
688,490
699,489
731,684
731,684699,489688,490608,709653,659450,743498,654536,884619,604602,916545,566454,962452,733373,443425,022364,736416,026378,388354,896306,429264,767215,856162,089137,366
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
105,483
105,586
91,505
91,595
0
091,59591,505105,586105,4830000000000000000000
       Accounts payable 
26,499
44,045
81,946
68,094
26,595
91,660
74,528
111,090
76,651
76,681
44,163
76,741
54,007
56,207
118,461
95,875
106,710
109,796
87,948
164,918
91,536
107,417
118,774
214,442
214,442118,774107,41791,536164,91887,948109,796106,71095,875118,46156,20754,00776,74144,16376,68176,651111,09074,52891,66026,59568,09481,94644,04526,499
       Other Current Liabilities 
6,762
7,413
8,944
11,146
12,463
14,837
15,553
22,139
18,205
18,956
19,027
15,051
17,803
16,416
26,213
15,489
17,381
16,992
17,951
0
16,270
17,128
17,289
0
017,28917,12816,270017,95116,99217,38115,48926,21316,41617,80315,05119,02718,95618,20522,13915,55314,83712,46311,1468,9447,4136,762
   > Long-term Liabilities 
477,965
486,497
491,410
739,868
1,496,131
1,485,281
1,510,229
1,806,933
1,865,052
1,848,943
1,819,247
1,767,232
1,744,306
1,724,830
2,122,393
2,123,812
1,810,153
1,885,825
1,894,607
1,751,580
1,654,484
1,658,698
1,679,374
1,703,747
1,703,7471,679,3741,658,6981,654,4841,751,5801,894,6071,885,8251,810,1532,123,8122,122,3931,724,8301,744,3061,767,2321,819,2471,848,9431,865,0521,806,9331,510,2291,485,2811,496,131739,868491,410486,497477,965
       Long term Debt 
425,752
431,040
436,421
681,900
687,953
694,156
700,470
992,493
1,091,110
1,092,985
1,094,912
1,096,876
1,098,847
1,100,873
1,542,770
1,544,292
1,234,284
1,235,517
1,236,755
1,132,515
1,133,660
1,134,810
1,135,965
1,137,124
1,137,1241,135,9651,134,8101,133,6601,132,5151,236,7551,235,5171,234,2841,544,2921,542,7701,100,8731,098,8471,096,8761,094,9121,092,9851,091,110992,493700,470694,156687,953681,900436,421431,040425,752
       Capital Lease Obligations Min Short Term Debt
52,165
50,209
49,741
47,720
65,263
72,401
68,229
80,367
60,675
65,285
63,428
41,512
38,620
39,368
35,229
73,067
53,931
129,170
134,752
158,810
140,102
143,601
170,009
205,946
205,946170,009143,601140,102158,810134,752129,17053,93173,06735,22939,36838,62041,51263,42865,28560,67580,36768,22972,40165,26347,72049,74150,20952,165
       Long-term Liabilities Other 
0
0
0
10,248
10,248
10,248
55,548
70,585
71,784
71,440
64,169
54,600
54,600
54,600
36,900
36,942
36,938
36,138
38,100
41,100
55,722
55,287
48,400
49,150
49,15048,40055,28755,72241,10038,10036,13836,93836,94236,90054,60054,60054,60064,16971,44071,78470,58555,54810,24810,24810,248000
> Total Stockholder Equity
1,348,564
1,099,167
995,204
818,187
1,144,828
1,042,866
892,047
761,759
535,445
485,108
469,528
928,009
856,886
726,457
430,840
384,950
712,749
741,411
764,357
859,337
961,192
1,077,069
1,221,071
1,527,742
1,527,7421,221,0711,077,069961,192859,337764,357741,411712,749384,950430,840726,457856,886928,009469,528485,108535,445761,759892,0471,042,8661,144,828818,187995,2041,099,1671,348,564
   Common Stock000000000000000000000000
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 000000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,901,979
Cost of Revenue-319,099
Gross Profit1,582,8801,582,880
 
Operating Income (+$)
Gross Profit1,582,880
Operating Expense-1,683,898
Operating Income218,081-101,018
 
Operating Expense (+$)
Research Development804,522
Selling General Administrative557,872
Selling And Marketing Expenses0
Operating Expense1,683,8981,362,394
 
Net Interest Income (+$)
Interest Income71,767
Interest Expense-18,391
Other Finance Cost-0
Net Interest Income53,376
 
Pretax Income (+$)
Operating Income218,081
Net Interest Income53,376
Other Non-Operating Income Expenses0
Income Before Tax (EBT)260,774228,764
EBIT - interestExpense = -18,391
235,239
253,630
Interest Expense18,391
Earnings Before Interest and Taxes (EBIT)0279,165
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax260,774
Tax Provision-25,535
Net Income From Continuing Ops235,239235,239
Net Income235,239
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-10,683-53,376
 

Technical Analysis of SAREPTA THERAP (AB3A.SG)
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of SAREPTA THERAP (AB3A.SG). The general trend of SAREPTA THERAP (AB3A.SG) is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine SAREPTA THERAP (AB3A.SG)'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of SAREPTA THERAP (AB3A.SG).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 98.08 < 114.25 < 122.40.

The bearish price targets are: 88.78 > 81.84 > 81.74.

Tweet this
SAREPTA THERAP (AB3A.SG) Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of SAREPTA THERAP (AB3A.SG). The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

SAREPTA THERAP (AB3A.SG) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily Moving Average Convergence/Divergence (MACD) ChartSAREPTA THERAP (AB3A.SG) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of SAREPTA THERAP (AB3A.SG). The current adx is .

SAREPTA THERAP (AB3A.SG) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily Relative Strength Index (RSI) ChartSAREPTA THERAP (AB3A.SG) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily Stochastic Oscillator ChartSAREPTA THERAP (AB3A.SG) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily Commodity Channel Index (CCI) ChartSAREPTA THERAP (AB3A.SG) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily Chande Momentum Oscillator (CMO) ChartSAREPTA THERAP (AB3A.SG) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily Williams %R ChartSAREPTA THERAP (AB3A.SG) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily Average True Range (ATR) ChartSAREPTA THERAP (AB3A.SG) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily On-Balance Volume (OBV) ChartSAREPTA THERAP (AB3A.SG) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of SAREPTA THERAP (AB3A.SG).

SAREPTA THERAP (AB3A.SG) Daily Money Flow Index (MFI) ChartSAREPTA THERAP (AB3A.SG) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for SAREPTA THERAP (AB3A.SG).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-29ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-03ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

SAREPTA THERAP (AB3A.SG) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of SAREPTA THERAP (AB3A.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose90.700
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of SAREPTA THERAP (AB3A.SG) with someone you think should read this too:
  • Are you bullish or bearish on SAREPTA THERAP (AB3A.SG)? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about SAREPTA THERAP (AB3A.SG)? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about SAREPTA THERAP (AB3A.SG)

I send you an email if I find something interesting about SAREPTA THERAP (AB3A.SG).


Comments

How you think about this?

Leave a comment

Stay informed about SAREPTA THERAP (AB3A.SG).

Receive notifications about SAREPTA THERAP (AB3A.SG) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.